MedPath

Telemonitoring in NIV MND (OptNIVent)

Not Applicable
Conditions
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Other: Telemonitoring via Careportal®
Registration Number
NCT05299372
Lead Sponsor
Liverpool University Hospitals NHS Foundation Trust
Brief Summary

This is a feasibility study of telemonitoring system for people with MND/ALS, who are on NIV, via a call centre operated by a local clinical commissioning group.

Detailed Description

This study will test the feasibility of previously developed Telehealth system, using a device called Careportal®, to monitor people with MND/ALS who are using non-invasive ventilation (NIV). The Careportal® is a CE marked portable tablet computer device allowing telecommunication between patients and their care team through bespoke question sets, overnight oximetry test, and patient-ventilator interaction(PVI) data. Previously, the weekly telemonitoring via Careportal® was found to be an effective method to monitor symptom changes, allowing clinicians to optimise the care of ventilated patients with MND. This study will assess the practicality of using Careportal® in the care of ventilated patients with MND by monitoring patients through a patient support call centre. The call centre will screen the data and liaise with appropriate clinicians regarding changes of symptoms.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Telemonitoring via Careportal®Telemonitoring via Careportal®Participants will be prompted by the device to answer two sets of questions every week: 10 items (1 nested) in the morning and 16 items (4 nested) in the evening. Also on a weekly basis, patients will be prompted to perform overnight oximetry test, and upload patient-ventilator interaction data (PVI) via Careportal®.
Primary Outcome Measures
NameTimeMethod
Acceptability - Qualitative data through semi-structured interviews and focus groupsQualitative data will be conducted at 3-month

Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.

Usability - Qualitative data through semi-structured interviews and focus groupsQualitative data will be conducted at 3-month

Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.

Secondary Outcome Measures
NameTimeMethod
Patient Reported Outcome Measurement - revised Amyotrophic Lateral Sclerosis Functional Rating ScaleBaseline and at 3-month and 6-month

12-item questionnaire to monitor the disease progression covering bulbar, motor and respiratory function. Total scores range from 0 to 48. Higher scores indicate better function.

Patient Reported Outcome Measurement - Epworth Sleepiness ScaleBaseline and then 6-weekly up to 24 weeks

8-item questionnaire to measure general levels of sleepiness. Total scores range from 0 to 24. Higher scores indicate higher levels of sleepiness.

Patient Reported Outcome Measurement - Access, Availability and ConvenienceBaseline and at 3-month and 6-month

12-item Access, Availability and Convenience sub-scale from Patient Satisfaction Questionnaire. Total scores range from 12 to 60. Higher scores indicate greater access, availability and convenience.

Patient Reported Outcome Measurement - Hospital Anxiety and Depression ScaleBaseline and at 3-month and 6-month

14-item questionnaire to measure anxiety and depression levels. The questionnaire consists of anxiety sub-scale and depression sub-scale. Scores for each sub-scale range from 0 to 21. Higher scores indicate greater anxiety/depression levels.

Self-Reported Outcome Measurement - Caregiving Distress ScaleBaseline and at 3-month and 6-month

17-item questionnaire to measure caregiver distress, covering five dimensions: Relationship distress, Emotional burden, Social impact, Care-receiver demands, and Personal cost. Total scores range from 0 to 68. Higher scores indicate greater distress.

Patient Reported Outcome Measurement - Dyspnoea-12Baseline and then 6-weekly up to 24 weeks

12-item questionnaire to measure overall breathlessness severity. Total scores range from 0 to 36. Higher scores indicate higher breathless severity.

Patient Reported Outcome Measurement - General SatisfactionBaseline and at 3-month and 6-month

6-item General Satisfaction sub-scale from Patient Satisfaction Questionnaire. Total scores range from 6 to 30. Higher scores indicate greater satisfaction.

Patient Reported Outcome Measurement - Neurological Fatigue Index for MNDBaseline and then 6-weekly up to 24 weeks

13-item questionnaire assessing fatigue experienced by people with motor neurone disease. The questionnaire consists of two sub-scales: Weakness sub-scale and Energy sub-scale. Eight items make up the Summary Fatigue scale with the total scores range from 0 to 24. Higher scores indicate higher levels of fatigue

Patient Reported Outcome Measurement - the World Health Organization Quality of Life Scale-BREFBaseline and at 3-month and 6-month

26-item questionnaire consists of Physical Health domain, Psychological domain, Social relationships domain, and Environment domain in addition to Overall QoL (1-item) and General Health (1-item) facets. Total scores range from 0 to 100. Higher scores indicate indicate higher quality of life.

Patient Reported Outcome Measurement - 5-level EQ-5DBaseline and at 3-month and 6-month

The questionnaire consists of 5-item to measure health based on five domains: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 levels indicating worsening health, from having no problems to having severe problems. The questionnaire also contain one visual analogue scale measuring health-reported health: 0 indicates worst health while 100 indicates the best health.

Service evaluationAt the end of study i.e. at 6-month

Patient Level Information and Costing System (PLICS)

© Copyright 2025. All Rights Reserved by MedPath